by Rna Diagnostics | May 27, 2026 | Rna News
Toronto, Ont., Canada, May 27, 2026 — Rna Diagnostics Inc., a clinical-stage molecular diagnostics company, today announced that patient recruitment has been completed for BREVITY, the Company-sponsored prospective clinical trial evaluating the RNA Disruption Assay™...
by Rna Diagnostics | Feb 5, 2026 | Rna News
Toronto, Ont., Canada, Feb. 5, 2026 — The Ontario government is investing $1,157,000 in Rna Diagnostics – a clinical-stage molecular diagnostics company – through the Northern Ontario Heritage Fund Corporation (NOHFC). The funding will help Rna Diagnostics advance...
by Rna Diagnostics | Dec 8, 2025 | Rna News
Toronto, Ont., Canada, Dec. 8, 2025 — A new study by scientists at the Institute of Cancer Research (Oslo University Hospital) and Rna Diagnostics, a clinical-stage molecular diagnostics company, supports the use of the RNA disruption assay (RDA) to predict tumour...
by Rna Diagnostics | Feb 6, 2025 | Rna News
Dr. Terry Mamounas, MD, MPH, FACS Toronto, Ont., Canada, Feb. 6, 2025 – Rna Diagnostics, an innovative developer of a predictive biomarker technology for early-stage cancer care, is pleased to announce that Dr. Terry Mamounas, MD, MPH, FACS, one of the world’s...
by Rna Diagnostics | Feb 16, 2024 | Rna News
Toronto, Ont., – Rna Diagnostics, a Canadian cancer diagnostics company, is pleased to announce the results from phase 1 of the BREVITY (Breast Cancer Response Evaluation for Individualized Therapy) clinical trial – that aims to validate the utility of the RNA...
